Evidence tables
Evidence table 4.11a: Add-on drugs for inhaled steroids: Chromones
Evidence table 4.11b: Add-on drugs for inhaled steroids: Long acting or oral B2 agonists
Evidence table 4.11c: Add-on drugs for inhaled steroids: Anticholinergics
Evidence table 4.13a: Immunosuppresive agent
Evidence table 4.15: Mometasone Furoate dry powder inhalation evidence
Evidence table 4.19: Allergic bronchopulmonary aspergillosis
Evidence table 4.2: Ipratopium bromide
Evidence table 4.21: Aspirin intolerant asthma
Evidence table 4.22: Combined therapy of inhaled steroids and long acting B2 agonist
Evidence table 4.24a: Other preventor therapies - Chromones in children aged 5-12
Evidence table 4.24b: Other preventor therapies - Chromones in children aged <5
Evidence table 4.25: Budesonide vs beclomethasone
Evidence table 4.3a: Long acting B2 agonists in exercise induced asthma
Evidence table 4.3b: Ketotifen for exercise-induced asthma
Evidence table 4.3c: Theophyllines in exercise-induced asthma
Evidence table 4.3d: Leukotriene receptor antagonists in exercise induced asthma
Evidence table 4.3e: Anti-histamines for exercise-induced asthma
Evidence table 4.3f: Anti-cholinergic therapy for exercise-induced asthma
Evidence table 4.4a: Inhaled corticosteroid vs theophylline
Evidence table 4.4c: Inhaled corticosteroid vs leukotriene receptor antagonists
Evidence table 4.4d: Leukotriene receptor antagonists with short-acting beta-agonists
Evidence table 4.4j: Do Chromones work as first line preventor in children >5 years?
Evidence table 4.7: High dose step-down
ISBN 978 1 909103 70 2